Nebenwirkungen · Xgeva
XGEVA 120 mg solution for injection XGEVA 120 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 7
HOS-124640 · Präparat HOS-095905
The following convention has been used for the classification of the adverse reactions based on incidence rates in four phase III, two phase II clinical studies and post-marketing experience (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data. Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-30T11:39:12Z · SHA-256 128fc1cc30bb902fd35b573513956c486b321d921f1c9f82cbb86938b613ea4c · Passage 9cdbd521877f3c242d3ac39891abaa7e4443eeb98c378cb5f0445bce3d4e0222 · Zeichen 704–1230 im Abschnitt